0001179110-21-010820.txt : 20211210 0001179110-21-010820.hdr.sgml : 20211210 20211210160318 ACCESSION NUMBER: 0001179110-21-010820 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211208 FILED AS OF DATE: 20211210 DATE AS OF CHANGE: 20211210 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cavanaugh Sarah CENTRAL INDEX KEY: 0001709113 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15006 FILM NUMBER: 211485254 MAIL ADDRESS: STREET 1: C/O CELLDEX THERAPEUTICS, INC. STREET 2: 53 FRONTAGE ROAD, SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Celldex Therapeutics, Inc. CENTRAL INDEX KEY: 0000744218 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133191702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 BUSINESS PHONE: 908-200-7500 MAIL ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 FORMER COMPANY: FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19980828 FORMER COMPANY: FORMER CONFORMED NAME: T CELL SCIENCES INC DATE OF NAME CHANGE: 19920703 4 1 edgar.xml FORM 4 - X0306 4 2021-12-08 0 0000744218 Celldex Therapeutics, Inc. CLDX 0001709113 Cavanaugh Sarah C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD, SUITE 220 HAMPTON NJ 08827 0 1 0 0 SVP of Corp Affairs & Admin. Common Stock 2021-12-08 4 M 0 1857 9.0165 A 2265 D Common Stock 2021-12-08 4 M 0 5466 10.38 A 7731 D Common Stock 2021-12-08 4 S 0 7323 40.00 D 408 D Incentive Stock Option (Right to Buy) 9.0165 2021-12-08 4 M 0 1857 0.00 D 2028-06-13 Common Stock 1857 11458 D Incentive Stock Option (Right to Buy) 10.38 2021-12-08 4 M 0 5466 0.00 D 2030-06-18 Common Stock 5466 78534 D The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 10, 2021. 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. /s/ Sam Martin, attorney-in-fact for Sarah Cavanaugh 2021-12-10